DoH Policies screened during the period – 1 January 2026 – 31 March 2026
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- Delivering Care Refreshed Policy Framework
- NICE Clinical Guideline NG253 - Suspected sepsis in people aged 16 or over: recognition, assessment and early management (updates and replaces NG51)
- NICE Clinical Guideline NG254 - Suspected sepsis in under 16s: recognition, diagnosis and early management
- NICE Clinical Guideline NG255 - Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management
- NICE Technology Appraisal TA1119 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (review of TA663)
- NICE Technology Appraisal TA1120 - Avelumab with axitinib for untreated advanced renal cell carcinoma (review of TA645)
- NICE Technology Appraisal TA1121 - Acoramidis for treating transthyretin amyloidosis with cardiomyopathy
- NICE Technology Appraisal TA1122 - Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
- NICE Technology Appraisal TA1126 - Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
- NICE Technology Appraisal TA1127 - Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer
- NICE Technology Appraisal TA1128 - Targeted-release budesonide for treating primary IgA nephropathy (review of TA937)
- NICE Technology Appraisal TA1129 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673)
- NICE Technology Appraisal TA1130 - Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer
- NICE Technology Appraisal TA1131 - Obinutuzumab with mycophenolate mofetil for treating lupus nephritis
- NICE Technology Appraisal TA1133 - Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma
- NICE Technology Appraisal TA1134 - Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648)
- NICE Technology Appraisal TA1136 - Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (review of TA212 and partial review of TA118 & TA242)
- NICE Technology Appraisal TA1138 - Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer
- NICE Technology Appraisal TA1139 - Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment
- NICE Technology Appraisal TA1140 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (rapid review of TA1088)
- NICE Technology Appraisal TA1142 - Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
- NICE Technology Appraisal TA1143 - Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause
- The Firefighters’ Pension Scheme (Amendment) Regulations (NI) 2026 – Proposed updates to member contribution structure